View More View Less
  • 1 Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Belgyógyászati Intézet, Hematológia Tanszék Debrecen Nagyerdei krt. 98. 4032
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Bevezetés: A rituximabkezelés hatására elhúzódó B-sejt-depléció alakulhat ki, amely fokozott fertőzési kockázattal járhat. Célkitűzés: A fehérvérsejtszám, a CD19+ B- és a CD4+ T-lymphocyták számának, valamint az immunglobulin G-, A-, M-szintek változásának vizsgálata rituximabtartalmú kemoterápiában részesülő betegeknél, valamint a fertőzéses szövődmények felmérése és a vonatkozó irodalom áttekintése. Betegek és módszerek: Összesen 35 diffúz nagy B-sejtes lymphomás beteget vizsgáltak rituximab-cyclophosphamid-vincristin-doxorubicin-prednisolon (R-CHOP) terápia mellett. A perifériás vérben a B- és T-sejt-populációkat áramlási citometriával, az immunglobulin-szinteket szérum nefelometriával mérték. Eredmények: A kezelés hatására a CD19+ B-lymphocyták nem voltak kimutathatók a perifériás vérből, számuk a kezelést követő 12. hónaptól növekedett. Infekció a vizsgált betegcsoportban nem fordult elő. Következtetések: A rituximab hatására kialakuló B-sejt-depléció ebben a betegcsoportban is igazolható volt, súlyos vagy nem várt fertőzést nem tapasztaltak. Fokozott fertőzési kockázattal elsősorban (hosszabb) fenntartó rituximabkezelés mellett kell számolni. Orv. Hetil., 2012, 153, 1658–1666.

  • Abulayha, A. M., Tabal, S. A., Shawesh, E. I., et al.: Depletion of peripheral blood B cells with rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma. Leuk. Res., 2010, 34, 307–311.

    Shawesh E. I. , 'Depletion of peripheral blood B cells with rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma ' (2010 ) 34 Leuk. Res. : 307 -311.

    • Search Google Scholar
  • Wolach, O., Bairey, O., Lahav, M.: Late-onset neutropenia after rituximab treatment. Case series and comprehensive review of the literature. Medicine, 2010, 89, 308–318.

    Lahav M. , 'Late-onset neutropenia after rituximab treatment. Case series and comprehensive review of the literature ' (2010 ) 89 Medicine : 308 -318.

    • Search Google Scholar
  • Gea-Banadoche, J. C.: Rituximab-associated infections. Semin. Hematol., 2010, 47, 187–198.

    Gea-Banadoche J. C. , 'Rituximab-associated infections ' (2010 ) 47 Semin. Hematol. : 187 -198.

    • Search Google Scholar
  • Kelesidis, T., Daikos, G., Boumpas, D., et al.: Does rituximab increase the incidence of infectious complications? Int. J. Inf. Dis., 2011, 15, e2–e16.

    Boumpas D. , 'Does rituximab increase the incidence of infectious complications? ' (2011 ) 15 Int. J. Inf. Dis. : e2 -e16.

    • Search Google Scholar
  • Kurokawa, T., Hase, M., Tokuman, N., et al.: Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol. Oncol., 2011, 29, 5–9.

    Tokuman N. , 'Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab ' (2011 ) 29 Hematol. Oncol. : 5 -9.

    • Search Google Scholar
  • Anolik, J. H., Friedberg, J. W., Zheng, B., et al.: B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin. Immunol., 2007, 122, 139–145.

    Zheng B. , 'B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny ' (2007 ) 122 Clin. Immunol. : 139 -145.

    • Search Google Scholar
  • Irie, E., Shirota, Y., Suzuki, C., et al.: Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int. J. Hematol., 2010, 91, 501–508.

    Suzuki C. , 'Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis ' (2010 ) 91 Int. J. Hematol. : 501 -508.

    • Search Google Scholar
  • Carbone, J., del Pozo, N., Gallego, A., et al.: Immunological risk factors for infection after immunosuppressive and biologic therapies. Expert Rev. Anti Infect. Ther., 2011, 9, 405–413.

    Gallego A. , 'Immunological risk factors for infection after immunosuppressive and biologic therapies ' (2011 ) 9 Expert Rev. Anti Infect. Ther. : 405 -413.

    • Search Google Scholar
  • Nishio, M., Fujimoto, K., Yamamoto, S., et al.: Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur. J. Hematol., 2006, 77, 226–232.

    Yamamoto S. , 'Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma ' (2006 ) 77 Eur. J. Hematol. : 226 -232.

    • Search Google Scholar
  • Wilk, E., Witte, T., Marquardt, N., et al.: Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum., 2009, 60, 3563–3571.

    Marquardt N. , 'Depletion of functionally active CD20+ T cells by rituximab treatment ' (2009 ) 60 Arthritis Rheum. : 3563 -3571.

    • Search Google Scholar
  • Lund, F. E., Hollifield, M., Schuler, K., et al.: B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J. Immunol., 2006, 176, 6147–6154.

    Schuler K. , 'B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection ' (2006 ) 176 J. Immunol. : 6147 -6154.

    • Search Google Scholar
  • Ratanatharathorn, V., Pavletic, S., Uberti, J. P.: Clinical application of rituximab in allogenic stem cell transplantation: anti-tumor and immunomodulatory effects. Cancer Treat. Rev., 2009, 35, 653–661.

    Uberti J. P. , 'Clinical application of rituximab in allogenic stem cell transplantation: anti-tumor and immunomodulatory effects ' (2009 ) 35 Cancer Treat. Rev. : 653 -661.

    • Search Google Scholar
  • Nitta, E., Izutsu, K., Sato, T., et al.: A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann. Oncol., 2007, 18, 364–369.

    Sato T. , 'A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study ' (2007 ) 18 Ann. Oncol. : 364 -369.

    • Search Google Scholar
  • Kimby, E.: Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev., 2005, 31, 456–473.

    Kimby E. , 'Tolerability and safety of rituximab (MabThera) ' (2005 ) 31 Cancer Treat. Rev. : 456 -473.

    • Search Google Scholar
  • Lanini, S., Molloy, A. C., Fine, P. E., et al.: Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med., 2011, 9, 36.

    Fine P. E. , 'Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis ' (2011 ) 9 BMC Med. : 36 -.

    • Search Google Scholar
  • Aksoy, S., Dizdar, O., Hayran, M., et al.: Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk. Lymphoma, 2009, 50, 357–365.

    Hayran M. , 'Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis ' (2009 ) 50 Leuk. Lymphoma : 357 -365.

    • Search Google Scholar
  • Vidal, L., Gafter-Gvili, A., Leibovici, L., et al.: Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst. Rev., 2009, 2, CD006552.

    Leibovici L. , 'Rituximab as maintenance therapy for patients with follicular lymphoma ' (2009 ) 2 Cochrane Database Syst. Rev. : CD006552 -.

    • Search Google Scholar
  • Salles, G., Seymour, J. F., Offner, F., et al.: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, 2011, 377, 42–51.

    Offner F. , 'Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial ' (2011 ) 377 Lancet : 42 -51.

    • Search Google Scholar
  • Kaplan, L. D., Lee, J. Y., Ambinder, R. F., et al.: Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 2005, 106, 1538–1543.

    Ambinder R. F. , 'Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010 ' (2005 ) 106 Blood : 1538 -1543.

    • Search Google Scholar
  • Carroll, M. B.: The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin. Biol. Ther., 2011, 11, 533–544.

    Carroll M. B. , 'The impact of biologic response modifiers on hepatitis B virus infection ' (2011 ) 11 Expert Opin. Biol. Ther. : 533 -544.

    • Search Google Scholar
  • Ohishi, W., Chayama, K.: Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy. Clin. Exp. Nephrol., 2011, 15, 634–640.

    Chayama K. , 'Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy ' (2011 ) 15 Clin. Exp. Nephrol. : 634 -640.

    • Search Google Scholar
  • Francisci, D., Falcinelli, F., Schiaroli, E., et al.: Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection, 2010, 38, 58–61.

    Schiaroli E. , 'Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy ' (2010 ) 38 Infection : 58 -61.

    • Search Google Scholar
  • Saag, K., Teng, G. G., Patkar, N. M., et al.: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum., 2008, 59, 762–784.

    Patkar N. M. , 'American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis ' (2008 ) 59 Arthritis Rheum. : 762 -784.

    • Search Google Scholar
  • Weissert, R.: Progressive multifocal leukoencephalopathy. J. Neuroimmunol., 2011, 231, 73–77.

    Weissert R. , 'Progressive multifocal leukoencephalopathy ' (2011 ) 231 J. Neuroimmunol. : 73 -77.

    • Search Google Scholar
  • Berger, J. R.: Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf., 2010, 33, 969–983.

    Berger J. R. , 'Progressive multifocal leukoencephalopathy and newer biological agents ' (2010 ) 33 Drug Saf. : 969 -983.

    • Search Google Scholar
  • Tuccori, M., Focosi, D., Blandizzi, C., et al.: Inclusion of rituximab in the treatment protocols for non-Hodgkin’s lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist, 2010, 15, 1214–1219.

    Blandizzi C. , 'Inclusion of rituximab in the treatment protocols for non-Hodgkin’s lymphomas and risk for progressive multifocal leukoencephalopathy ' (2010 ) 15 Oncologist : 1214 -1219.

    • Search Google Scholar
  • Kamel, S., O’Connor, S., Lee, N., et al.: High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk. Lymphoma, 2010, 51, 797–801.

    Lee N. , 'High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone ' (2010 ) 51 Leuk. Lymphoma : 797 -801.

    • Search Google Scholar
  • Hugle, B., Solomon, M., Harvey, E., et al.: Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener’s granulomatosis. Arthritis Care Res. (Hoboken), 2010, 62, 1661–1664.

    Harvey E. , 'Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener’s granulomatosis ' (2010 ) 62 Arthritis Care Res. (Hoboken) : 1661 -1664.

    • Search Google Scholar
  • Tadmor, T., McLaughlin, P., Polliack, A.: A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen? Leuk. Lymphoma, 2010, 51, 737–738.

    Polliack A. , 'A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen? ' (2010 ) 51 Leuk. Lymphoma : 737 -738.

    • Search Google Scholar
  • Van Assen, S., Elkayam, O., Agmon-Levin, N., et al.: Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun. Rev., 2011, 10, 341–352.

    Agmon-Levin N. , 'Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases ' (2011 ) 10 Autoimmun. Rev. : 341 -352.

    • Search Google Scholar
  • Takata, T., Suzumiya, J., Ishikawa, T., et al.: Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J. Clin. Exp. Hematopathol., 2009, 49, 9–13.

    Ishikawa T. , 'Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP ' (2009 ) 49 J. Clin. Exp. Hematopathol. : 9 -13.

    • Search Google Scholar
  • Bedognetti, D., Zoppoli, G., Massucco, C., et al.: Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximab-containing regimens. J. Immunology, 2011, 186, 6044–6055.

    Massucco C. , 'Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximab-containing regimens ' (2011 ) 186 J. Immunology : 6044 -6055.

    • Search Google Scholar
  • Yri, O. E., Torfoss, D., Hungnes, O., et al.: Rituximab blocks protective serological response to influenza A(H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood, 2011, 118, 6769–6771.

    Hungnes O. , 'Rituximab blocks protective serological response to influenza A(H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment ' (2011 ) 118 Blood : 6769 -6771.

    • Search Google Scholar
  • Centkowski, P., Brydak, L., Machala, M., et al.: Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. J. Clin. Immunol., 2007, 27, 339–346.

    Machala M. , 'Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma ' (2007 ) 27 J. Clin. Immunol. : 339 -346.

    • Search Google Scholar